Aveanna Healthcare is rated Buy due to its double-digit revenue growth, improved operational efficiency, and a favorable California Medicaid rate increase expected in 2027. The company trades at a roughly 20% earnings discount compared to peers, reflecting market concerns over its leverage and Medicaid dependency. However, rising caregiver wages, expanding nursing hours, and operational efficiencies support further growth potential. Key risks include wage inflation outpacing reimbursements, high floating-rate debt, and reliance on Medicaid funding, making monitoring of state rates and leverage important.
Aveanna Healthcare shares are trading at USD 12.25 on Pluang as of Nov 13, 2026 09:31 WIB, down 6.42% in the last day. Despite the company's double-digit revenue growth and operational improvements highlighted in the news, the stock remains below its 52-week high of USD 14.38 and above its low of USD 6.22. The market cap stands at $2.86 billion with a volume of 1,656,675 shares, and all recent Pluang order activity is on the buy side, reflecting investor interest amid ongoing concerns about leverage and Medicaid dependency.
Aveanna Healthcare Holdings Inc. reported strong Q3 2026 results, surpassing analyst expectations on both revenue and earnings. The company’s adjusted EBITDA increased by 25% year-over-year, with margins expanding to 14.4%, signaling improved operati...
Aveanna Healthcare Holdings announced its third quarter 2026 financial results with revenue of $695.5 million, up 11.8% year-over-year, and net income of $45.5 million, significantly higher than the previous year's $14.1 million. Adjusted EBITDA rose...
